Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS - a Randomised, Placebo-controlled, Double-blind Trial

Next Previous
X
Search
Trial Profile

Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS - a Randomised, Placebo-controlled, Double-blind Trial

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Solnatide (Primary)
  • Indications Adult respiratory distress syndrome; Pulmonary oedema
  • Focus Adverse reactions
  • Sponsors APEPTICO Forschung und Entwicklung

    • Most Recent Events

    • 09 Feb 2024 Planned End Date changed from 1 Jun 2024 to 1 Dec 2024.
    • 09 Feb 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Dec 2024.
    • 24 Jul 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top